US Patent No.9, 487,560 : Angiogenic active lytic peptides
November 8, 2016
Because the modulation of angiogenesis has been shown to be a significant causative factor in the control of certain disorders and diseases, it is necessary to find agents which are safe and efficacious in either inhibiting or stimulating angiogenesis. ISSAR has developed NOVEL SYNTHETIC LYTIC PEPTIDES (PATENTED) which takes care of most of the problems associated with the angiogenesis disorders. It effectively helps in enhancing or inhibiting the angiogenesis and therefore becomes effective therapeutic agent for several diseases associated with angiogenesis.
A Diagrammatic Representation of Angiogenesis _____________________________________________________________________
Initially 70 sequences were identified as angiogenic lytic peptides and screened and studied in the patent. The patent explains how lytic peptides can be Anti angiogenic and Anti-Inflammatory molecules and how active in eliminating tumour derived cells by causing direct osmotic lysis. Based on this demonstrable activity, it was inferred that in order to demonstrate in vivo activity the peptide must be injected directly into the tumour. With just a few injections over a period of several days, tumours are permanently eliminated.
Finally one lead peptide was identified as potent angiogenic lytic peptide. This peptide can be screened for anti-inflammatory activity which aides treating disorders or diseases which involves angiogenisis and chronic inflammatory related disorders or conditions selected from among arthritis, ulcerative colitis, Crohn’s disease, cancer, multiple sclerosis, cervical spondylosis, tinnitus, systemic lupus erythematosis (SLE), Sepsis, graft rejection, psoriasis, arteriosclerosis, hypertension, ischemia-reperfusion and also for few Orphan diseases Like Age-Related Macular Degeneration(AMD).